111 related articles for article (PubMed ID: 36261752)
21. Practice Variation in the Adjuvant Treatment of Colon Cancer in the Netherlands: A Population-based Study.
Keikes L; Koopman M; Lemmens VEPP; VAN Oijen MGH; Punt CJA
Anticancer Res; 2020 Aug; 40(8):4331-4341. PubMed ID: 32727761
[TBL] [Abstract][Full Text] [Related]
22. A Population-Based Cohort Study of Venous Thromboembolism Rates Following Surgery and During Adjuvant Chemotherapy in Patients With Colon Cancer.
Patel SV; Zhang L; Wei XS; Merchant SJ; Nanji S; James PD; Booth CM
Dis Colon Rectum; 2020 Mar; 63(3):336-345. PubMed ID: 32045399
[TBL] [Abstract][Full Text] [Related]
23. Risk of metachronous peritoneal metastases in patients with pT4a versus pT4b colon cancer: An international multicentre cohort study.
Bastiaenen VP; Aalbers AGJ; Arjona-Sánchez A; Bellato V; van der Bilt JDW; D'Hoore AD; Espinosa-Redondo E; Klaver CEL; Nagtegaal ID; van Ramshorst B; van Santvoort HC; Sica GS; Snaebjornsson P; Wasmann KATGM; de Wilt JHW; Wolthuis AM; Tanis PJ
Eur J Surg Oncol; 2021 Sep; 47(9):2405-2413. PubMed ID: 34030920
[TBL] [Abstract][Full Text] [Related]
24. Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study.
André T; de Gramont A; Vernerey D; Chibaudel B; Bonnetain F; Tijeras-Raballand A; Scriva A; Hickish T; Tabernero J; Van Laethem JL; Banzi M; Maartense E; Shmueli E; Carlsson GU; Scheithauer W; Papamichael D; Möehler M; Landolfi S; Demetter P; Colote S; Tournigand C; Louvet C; Duval A; Fléjou JF; de Gramont A
J Clin Oncol; 2015 Dec; 33(35):4176-87. PubMed ID: 26527776
[TBL] [Abstract][Full Text] [Related]
25. A national evaluation of the use and survival impact of adjuvant chemotherapy in Stage II colon cancer from the national cancer database.
Reif de Paula T; Gorroochurn P; Simon HL; Haas EM; Keller DS
Colorectal Dis; 2022 Jan; 24(1):40-49. PubMed ID: 34605166
[TBL] [Abstract][Full Text] [Related]
26. Prognostic and predictive roles of DNA mismatch repair status in colon cancer patients treated with oxaliplatin-based chemotherapy: a retrospective study.
Qin Q; Zhou AP; Yang L; Xu C; Sun YK; Zhang W; Wang JW; Zhong DS
J Physiol Pharmacol; 2020 Aug; 71(4):. PubMed ID: 33316771
[TBL] [Abstract][Full Text] [Related]
27. Influence of KRAS mutations on clinical outcome in patients with curatively resected stage III colon cancer treated with adjuvant chemotherapy.
De Dosso S; Nucifora M; Sahnane N; Epistolio S; Riveiro ME; Bertolini V; Bucci E; Boldorini R; Freguia S; Frattini M; Saletti P
Eur Rev Med Pharmacol Sci; 2020 Mar; 24(6):2994-3003. PubMed ID: 32271417
[TBL] [Abstract][Full Text] [Related]
28. Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer.
Tie J; Cohen JD; Wang Y; Christie M; Simons K; Lee M; Wong R; Kosmider S; Ananda S; McKendrick J; Lee B; Cho JH; Faragher I; Jones IT; Ptak J; Schaeffer MJ; Silliman N; Dobbyn L; Li L; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
JAMA Oncol; 2019 Dec; 5(12):1710-1717. PubMed ID: 31621801
[TBL] [Abstract][Full Text] [Related]
29. Effect of adjuvant chemotherapy on survival benefit in stage III colon cancer patients stratified by age: a Japanese real-world cohort study.
Kawamura H; Morishima T; Sato A; Honda M; Miyashiro I
BMC Cancer; 2020 Jan; 20(1):19. PubMed ID: 31906959
[TBL] [Abstract][Full Text] [Related]
30. Controversial Issues Regarding Obligatory Adjuvant Chemotherapy for Stage IIIA Colon Cancer.
Kim CW; Kim TW; Lee JL; Park IJ; Yoon YS; Lim SB; Yu CS; Kim JC
Clin Colorectal Cancer; 2020 Dec; 19(4):e157-e163. PubMed ID: 32896486
[TBL] [Abstract][Full Text] [Related]
31. S-1 and oxaliplatin versus tegafur-uracil and leucovorin as post-operative adjuvant chemotherapy in patients with high-risk stage III colon cancer: updated 5-year survival of the phase III ACTS-CC 02 trial.
Watanabe J; Sasaki S; Kusumoto T; Sakamoto Y; Yoshida K; Tomita N; Maeda A; Teshima J; Yokota M; Tanaka C; Yamauchi J; Uetake H; Itabashi M; Takahashi K; Baba H; Kotake K; Boku N; Aiba K; Morita S; Takenaka N; Sugihara K
ESMO Open; 2021 Apr; 6(2):100077. PubMed ID: 33714860
[TBL] [Abstract][Full Text] [Related]
32. Adjuvant chemotherapy for stage III colon cancer: relative dose intensity and survival among veterans.
Aspinall SL; Good CB; Zhao X; Cunningham FE; Heron BB; Geraci M; Passero V; Stone RA; Smith KJ; Rogers R; Shields J; Sartore M; Boyle DP; Giberti S; Szymanski J; Smith D; Ha A; Sessions J; Depcinski S; Fishco S; Molina I; Lepir T; Jean C; Cruz-Diaz L; Motta J; Calderon-Vargas R; Maland J; Keefe S; Tague M; Leone A; Glovack B; Kaplan B; Cosgriff S; Kaster L; Tonnu-Mihara I; Nguyen K; Carmichael J; Clifford L; Lu K; Chatta G
BMC Cancer; 2015 Feb; 15():62. PubMed ID: 25884851
[TBL] [Abstract][Full Text] [Related]
33. Impact of relative dose intensity of oxaliplatin in adjuvant therapy among stage III colon cancer patients on early recurrence: a retrospective cohort study.
Żok J; Bieńkowski M; Radecka B; Korniluk J; Adamowicz K; Duchnowska R
BMC Cancer; 2021 May; 21(1):529. PubMed ID: 33971834
[TBL] [Abstract][Full Text] [Related]
34. Impact of timing of adjuvant chemotherapy on survival in stage III colon cancer: a population-based study.
Gao P; Huang XZ; Song YX; Sun JX; Chen XW; Sun Y; Jiang YM; Wang ZN
BMC Cancer; 2018 Mar; 18(1):234. PubMed ID: 29490625
[TBL] [Abstract][Full Text] [Related]
35. Survival and Prognostic Factors for Metachronous Peritoneal Metastasis in Patients with Colon Cancer.
Nagata H; Ishihara S; Hata K; Murono K; Kaneko M; Yasuda K; Otani K; Nishikawa T; Tanaka T; Kiyomatsu T; Kawai K; Nozawa H; Watanabe T
Ann Surg Oncol; 2017 May; 24(5):1269-1280. PubMed ID: 27995451
[TBL] [Abstract][Full Text] [Related]
36. Irinotecan and Oxaliplatin Might Provide Equal Benefit as Adjuvant Chemotherapy for Patients with Resectable Synchronous Colon Cancer and Liver-confined Metastases: A Nationwide Database Study.
Liang YH; Shao YY; Chen HM; Cheng AL; Lai MS; Yeh KH
Anticancer Res; 2017 Dec; 37(12):7095-7104. PubMed ID: 29187501
[TBL] [Abstract][Full Text] [Related]
37. Recurrence and cancer-specific death after adjuvant chemotherapy for Stage III colon cancer.
Chapuis PH; Bokey E; Chan C; Keshava A; Rickard MJFX; Stewart P; Young CJ; Dent OF
Colorectal Dis; 2019 Feb; 21(2):164-173. PubMed ID: 30253025
[TBL] [Abstract][Full Text] [Related]
38. Nutritional risk screening score is associated with omission of adjuvant chemotherapy for stage III colon cancer.
Lee SY; Yeom SS; Kim CH; Kim HR
Am J Surg; 2020 Oct; 220(4):993-998. PubMed ID: 32057413
[TBL] [Abstract][Full Text] [Related]
39. Identification of patients with high-risk stage II colon cancer for adjuvant therapy.
Quah HM; Chou JF; Gonen M; Shia J; Schrag D; Landmann RG; Guillem JG; Paty PB; Temple LK; Wong WD; Weiser MR
Dis Colon Rectum; 2008 May; 51(5):503-7. PubMed ID: 18322753
[TBL] [Abstract][Full Text] [Related]
40. Long-term results of 2 adjuvant trials reveal differences in chemosensitivity and the pattern of metastases between colon cancer and rectal cancer.
Kornmann M; Staib L; Wiegel T; Kron M; Henne-Bruns D; Link KH; Formentini A;
Clin Colorectal Cancer; 2013 Mar; 12(1):54-61. PubMed ID: 23107590
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
